

Clinical test report - Illustrative example

CGP panel

Report LOC-5834-8470 on 26 September 2023 at 15:15 (UTC+03:00)






Page 1/2

| Patient | | Order | | Sample | |
|---------------|---------------------|--------------------|-------------------|-------------|-------------|
| ID | 89238923 | Test | CGP panel | Sample ID | A123456 |
| Name | John Johnsson | Organisation | Varnon Hospital | Sample type | Whole blood |
| Date of Birth | 05 March 1958 | Assigned clinician | Christie McKenzie | | |
| Sex | Male | | | | |
| Cancer type | Lung Cancer (NSCLC) | | | | |

Summary of findings and conclusions

Summary of findings can be added here...

Variants and therapies

| Gene | cDNA change | Protein change | VAF % | Lab classification | Reference classifications |
|---------------------------|--|--------------------------------|--|--------------------|--|
| BRAF | c.1799T>A | V600E <i>p. (Val600Glu)</i> | 0.97 | Pathogenic | ClinVar Pathogenic ID: 13961 OncoKB Oncogenic |
| Related therapy options | | | | | |
| Therapy | EMA Approval | | FDA Approval (OncoKB levels of evidence) | | |
| Dabrafenib & Trametinib |  Effective Lung Cancer (NSCLC), Melanoma | |  L1 - FDA-recognized Non-Small Cell Lung Cancer, Thyroid Cancer, Melanoma  L2 - Standard care Biliary Tract Cancer, Histiocytosis, Glioma | | |
| ERBB2 | c.2033G>A | R678Q <i>p. (Arg678Gln)</i> | 4.50 | Pathogenic | ClinVar Likely pathogenic ID: 376344 OncoKB Oncogenic |
| Related therapy options | | | | | |
| Therapy | EMA Approval | | FDA Approval (OncoKB levels of evidence) | | |
| Ado-Trastuzumab Emtansine | | |  L2 - Standard care Non-Small Cell Lung Cancer | | |
| Trastuzumab Deruxtecan | | |  L1 - FDA-recognized Non-Small Cell Lung Cancer | | |

Other diagnostic conclusions

Other diagnostic conclusions are displayed here...

Literature links

Place for adding relevant literature links...

Other information

Other additional information can be added here...

Sign off Report signed off by Oscar Oscarsson, on 26 September 2023 at 15:15 (UTC+03:00)
Performing laboratory Varnon Hospital

Methodology description

Assay description

CGP panel (128 genes).

Genes included

AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARID1A, ATM, ATR, AURKA, BAP1, BCL2L11, BRAF, BRCA1, BRCA2, CCND1, CCNE1, CD274, CDK12, CDK4, CDK6, CDKN2A, CDKN2B, CREBBP, CTNNB1, DDR2, EGFR, EIF1AX, EPAS1, EPCAM, ERBB2, ERBB3, ERBB4, ESR1, ETS2, FANCA, FBXW7, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLCN, FLT3, GNAS, HIF1A, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDM5C, KDR, KIT, KRAS, MAP2K1, MAPK1, MET, MLH1, MRE11, MSH2, MSH6, MTOR, MYC, NF1, NF2, NOTCH1, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PALB2, PAX8, PDCD1, PDGFRA, PGR, PIK3CA, PIK3R1, PMS2, POLD1, POLE, PSMD4, PTCH1, PTEN, RAF1, RASA1, RASAL1, RB1, RET, RICTOR, RIT1, ROS1, RSF1, SF3B1, SMAD4, SMARCA4, SMO, STK11, TERT, TOP2A, TP53, TSC1, TSC2, TSHR, VHL, ABCB1, C8orf34, CDA, CYP19A1, CYP2D6, DPYD, DYNC2H1, ERCC1, GSTP1, MTHFR, MTRR, SEMA3C, SLC28A3, SOD2, UGT1A1, UMPS, XPC, XRCC1

Other laboratory methods

Free text field here to describe for example the DNA extraction methods used by the lab....

Bioinformatics and reporting

P001-02 Hedera Prime (01)4260755740019(8012)1.20.0(21)eoo921
Hedera Prime (version local-b87866781c47f8b49677ca709fa920731b25e59c)
Hedera computational module (Fusion v0.5.0-rc)

Annotation sources

Allexes 2021-12-22
BRCA Exchange data version 2022-09-01
ClinVar 202111
ClinVar Custom Gene Annotations 202111
dbNSFP 3.4
dbSNP 142
GnomAD Exomes+Genomes 2.1.1
GnomAD Gene Annotations 2.1.1
Hedera Prime Therapy Options 2022-06-17
HPO Scores 2021-08
Mastermind 2021-04
OncoKB data version v3.16, v4.4
OncoKB data version v3.16, v4.5
SCSNV 1.1

Sign off Report signed off by Oscar Oscarsson, on 26 September 2023 at 15:15 (UTC+03:00)

Performing laboratory Varnon Hospital